Novartis: positive efficacy data in MS

(CercleFinance.com) - Novartis announces that the ALITHIOS open-label extension study evaluating its Kesimpta shows substantial efficacy benefits over six years in newly diagnosed, treatment-naive people with relapsing multiple sclerosis (MS).


Similar results were demonstrated in a separate analysis in the overall study population, and switching from teriflunomide to Kesimpta resulted in significant improvements in several efficacy endpoints in both analyses.

The Swiss healthcare group adds that treatment with Kesimpta for up to six years continues to be well tolerated with consistent safety results, supporting its favorable benefit-risk profile in relapsing MS.


Copyright (c) 2024 CercleFinance.com. All rights reserved.